GoutPhase 1NCT01744379
Single and Multiple Dose Study in Japanese
A Phase 1 study testing Lesinurad in people with Gout, run by Ardea Biosciences, Inc. at 1 site in United States.
Trial summary
This study will explore the safety, tolerability, and serum uric acid lowering effect of lesinurad in healthy Japanese males to allow comparison with the Western population. Read more about this study
- Who is it for?
- Ages 20 to 55 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Gout
- What is being tested?
- Lesinurad
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- Dec 2012to May 2013
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 55 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Able to understand the study procedures, the risks involved and willing to provide written Informed Consent before the first study related activity.
- Healthy adult subjects born in Japan
- All laboratory parameters should be within normal limits or considered not clinically significant by the investigator.
- Screening serum uric acid level >= 4.5 mg/dL.
- Subjects must be free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations or procedures.
- Subject does not have clinically relevant abnormalities in blood pressure, heart rate, body temperature, and respiratory rate, as per the Investigator's judgment.
Who cannot join
- Positive serology to Human Immunodeficiency Virus (HIV-1 and HIV-2).
- Positive test for active Hepatitis B or Hepatitis C infection.
- History of kidney stones.
- Undergone major surgery within 3 months of Day 1.
- Subject has received the last dose of an investigational drug (or treatment with a medical device) within 30 days or 5 half-lives (whichever is longer) of the investigational drug prior to Day 1 or are currently participating in another study of an investigational drug (or medical device).
- Prior exposure to lesinurad (RDEA594) or RDEA806.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of Lesinurad in Healthy Male Japanese Subjects
This study will explore the safety, tolerability, and serum uric acid lowering effect of lesinurad in healthy Japanese males to allow comparison with the Western population.
Read the detailed description
While there is extensive clinical experience with lesinurad in the Western population, it is recognized that both intrinsic and extrinsic factors may impact the PK, PD, safety, and dose response in different ethnic populations. The purpose of this study is to explore the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of single and multiple doses of lesinurad in healthy Japanese males, and to allow comparison of these parameters with the Western population.
- Conditions
- Gout
- Being tested
- Lesinurad, Placebo
- Medical subject headings
- Gout
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LesinuradDrug
PlaceboDrug
| Study group | Role | What they receive |
|---|---|---|
| 200 mg lesinurad | Experimental | 200 mg lesinurad or placebo fasted and fed Receives: Drug: Lesinurad; Drug: Placebo |
| 400 mg lesinurad | Experimental | 400 mg lesinurad or placebo fasted and fed Receives: Drug: Lesinurad; Drug: Placebo |
| 100 mg lesinurad | Experimental | 100 mg lesinurad or placebo fasted and fed Receives: Drug: Lesinurad; Drug: Placebo |
| 50 mg lesinurad | Experimental | 50 mg lesinurad or placebo fasted and fed Receives: Drug: Lesinurad; Drug: Placebo |
| 600 mg lesinurad | Experimental | 600 mg lesinurad or placebo fasted and fed Receives: Drug: Lesinurad; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Adverse Events and Changes in Laboratory Parameters
Measured: 5 to 6 weeks
Pharmacokinetic (PK) profile of lesinurad from plasma and urine in terms of AUC, tmax, cmax and t1/2.
AUC: area under the plasma concentration time curve from zero to 24 hours post dose and from zero to infinity; tmax: time to maximum plasma concentration; cmax: maximum observed plasma concentration t1/2: terminal elimination half life
Measured: Day -1 through 12
Pharmacodynamic (PD) profile of lesinurad from serum and urine in terms of sUA concentration, renal clearance, urine uric acid excretion, and fractional excretion.
Measured: Day 1 through 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Dec 2012 (estimated)
- Study startDec 2012
- Primary completionMar 2013
- Study completionMay 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GoutStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ardea Biosciences, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- S Bradley, MD, Study director, Ardea Biosciences, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01744379
- Sponsor's protocol ID
- RDEA594-125
- Status last verified
- Jun 2013
- First submitted
- 29 Nov 2012
- Last updated
- 19 Jun 2013
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Jun 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of Lesinurad in Healthy Male Japanese Subjects
- ClinicalTrials.gov ID
- NCT01744379
- Acronym / sponsor ID
- RDEA594-125
- Conditions
- Gout
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Ardea Biosciences, Inc.Industry (pharma, biotech, devices)
- Study start
- Dec 2012
- Primary completion
- Mar 2013 (actual)
- Study completion
- May 2013 (actual)
- First posted
- 6 Dec 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will explore the safety, tolerability, and serum uric acid lowering effect of lesinurad in healthy Japanese males to allow comparison with the Western population.
Detailed description
While there is extensive clinical experience with lesinurad in the Western population, it is recognized that both intrinsic and extrinsic factors may impact the PK, PD, safety, and dose response in different ethnic populations. The purpose of this study is to explore the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of single and multiple doses of lesinurad in healthy Japanese males, and to allow comparison of these parameters with the Western population.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| 200 mg lesinurad | Experimental | Drug: Lesinurad, Drug: Placebo200 mg lesinurad or placebo fasted and fed |
| 400 mg lesinurad | Experimental | Drug: Lesinurad, Drug: Placebo400 mg lesinurad or placebo fasted and fed |
| 100 mg lesinurad | Experimental | Drug: Lesinurad, Drug: Placebo100 mg lesinurad or placebo fasted and fed |
| 50 mg lesinurad | Experimental | Drug: Lesinurad, Drug: Placebo50 mg lesinurad or placebo fasted and fed |
| 600 mg lesinurad | Experimental | Drug: Lesinurad, Drug: Placebo600 mg lesinurad or placebo fasted and fed |
Who may qualify
- Ages
- 20 to 55 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Able to understand the study procedures, the risks involved and willing to provide written Informed Consent before the first study related activity.
- Healthy adult subjects born in Japan
- All laboratory parameters should be within normal limits or considered not clinically significant by the investigator.
- Screening serum uric acid level >= 4.5 mg/dL.
- Subjects must be free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations or procedures.
Key exclusion criteria (6 listed)
- Positive serology to Human Immunodeficiency Virus (HIV-1 and HIV-2).
- Positive test for active Hepatitis B or Hepatitis C infection.
- History of kidney stones.
- Undergone major surgery within 3 months of Day 1.
- Subject has received the last dose of an investigational drug (or treatment with a medical device) within 30 days or 5 half-lives (whichever is longer) of the investigational drug prior to Day 1 or are currently participating in another study of an investigational drug (or medical device).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lesinurad | Drug | 100 mg lesinurad, 200 mg lesinurad, 400 mg lesinurad, 50 mg lesinurad, 600 mg lesinurad |
| Placebo | Drug | 100 mg lesinurad, 200 mg lesinurad, 400 mg lesinurad, 50 mg lesinurad, 600 mg lesinurad |
Primary outcome
Incidence of Adverse Events and Changes in Laboratory Parameters
Time frame: 5 to 6 weeks
Pharmacokinetic (PK) profile of lesinurad from plasma and urine in terms of AUC, tmax, cmax and t1/2.
Time frame: Day -1 through 12
AUC: area under the plasma concentration time curve from zero to 24 hours post dose and from zero to infinity; tmax: time to maximum plasma concentration; cmax: maximum observed plasma concentration t1/2: terminal elimination half life
Pharmacodynamic (PD) profile of lesinurad from serum and urine in terms of sUA concentration, renal clearance, urine uric acid excretion, and fractional excretion.
Time frame: Day 1 through 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jun 2013.
Related trials for Gout
RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Gout
RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Tophaceous Gout
Not yet recruitingPhase 3
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
Gout Disease
Enrolling by invitation
The Remote Monitoring of Gout Study
Gout Initiating Urate-loweringUrate-lowering Therapy
Recruiting
Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout
Gout, Gouty Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
S Bradley, MD study director
Ardea Biosciences, Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Lesinurad in people with Gout, run by Ardea Biosciences, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Jun 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Adverse Events and Changes in Laboratory Parameters (time frame: 5 to 6 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jun 2013; AzTrials last refreshed its copy on 30 Oct 2026.